by Sundance at The Conservative Treehouse
Thinking about it, this certainly does appear to be a purchase based on self-interest. The company that manufactured a product, potentially creating long-term issues with blood disorders (ie clotting), now purchases the company that specializes in the treatment of blood disorders.
Am I the only one that sees this as sketchy?
Aug 8 (Reuters) – Pfizer Inc on Monday agreed to pay $5.4 billion in cash for Global Blood Therapeutics (GBT.O), as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing price. The deal is at a more than 40% premium where GBT was trading before the Wall Street Journal reported that Pfizer was in advanced talks to buy it on Thursday.
Pfizer’s 2021 revenue of $81.3 billion was nearly double the mark from the previous year…
Continue Reading